See more : Satin Creditcare Network Limited (SATIN.NS) Income Statement Analysis – Financial Results
Complete financial analysis of iBio, Inc. (IBIO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of iBio, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Adriatic Metals PLC (ADMLF) Income Statement Analysis – Financial Results
- Orion Acquisition Corp. (OHPAU) Income Statement Analysis – Financial Results
- Zhejiang Windey Co.,Ltd. (300772.SZ) Income Statement Analysis – Financial Results
- CCIAM Future Energy Limited (0145.HK) Income Statement Analysis – Financial Results
- Dr. Ing. h.c. F. Porsche AG (DRPRF) Income Statement Analysis – Financial Results
iBio, Inc. (IBIO)
About iBio, Inc.
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company operates in two segments: Biopharmaceuticals and Bioprocessing. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; and collaboration agreement with CC-Pharming Ltd. The company is headquartered in Bryan, Texas.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 225.00K | 0.00 | 2.38M | 2.37M | 1.64M | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 1.18M | 987.06K | 896.27K |
| Cost of Revenue | 0.00 | 1.11M | 216.00K | 1.46M | 703.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 500.84K | 485.13K | 445.72K |
| Gross Profit | 225.00K | -1.11M | 2.17M | 909.00K | 935.00K | 2.02M | 444.00K | 394.00K | 948.00K | 1.85M | 205.00K | 1.01M | 1.28M | 520.08K | 0.00 | 675.77K | 501.93K | 450.55K |
| Gross Profit Ratio | 100.00% | 0.00% | 90.94% | 38.34% | 57.08% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 57.43% | 50.85% | 50.27% |
| Research & Development | 5.19M | 10.33M | 17.73M | 9.99M | 3.21M | 5.47M | 3.99M | 4.12M | 3.16M | 3.50M | -150.00K | 3.43M | 4.98M | 3.08M | 2.52M | 797.40K | 550.00K | 673.23K |
| General & Administrative | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 11.67M | 19.02M | 34.13M | 22.03M | 12.43M | 12.33M | 10.69M | 10.55M | 7.69M | 5.02M | 4.20M | 4.24M | 5.62M | 7.09M | 2.07M | 1.80M | 1.82M | 1.44M |
| Other Expenses | 0.00 | 0.00 | 13.00K | 12.00K | 10.00K | 16.00K | 19.00K | 25.00K | 21.00K | 32.00K | 45.00K | 30.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.44M |
| Operating Expenses | 16.86M | 29.34M | 51.86M | 32.02M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 2.60M | 2.37M | 2.12M |
| Cost & Expenses | 16.86M | 29.34M | 52.07M | 33.48M | 15.64M | 17.81M | 14.67M | 14.67M | 10.84M | 8.52M | 4.05M | 7.67M | 10.60M | 10.17M | 4.59M | 3.10M | 2.85M | 2.56M |
| Interest Income | 363.00K | 130.00K | 178.00K | 140.00K | 15.00K | 75.00K | 15.00K | 39.00K | 22.00K | 9.00K | 130.00K | 9.00K | 11.67K | 12.62K | 12.73K | 20.42K | 0.00 | 0.00 |
| Interest Expense | 172.00K | 0.00 | 1.41M | 2.45M | 2.47M | 1.90M | 1.92M | 1.93M | 807.00K | 0.00 | 122.00K | 90.00K | 62.85K | 50.50K | 13.11K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.25M | 1.11M | 3.79M | 2.41M | 2.24M | 1.75M | 1.71M | 1.68M | 940.00K | 363.00K | 361.00K | 338.00K | 329.71K | 376.81K | 337.03K | 283.95K | 245.27K | 322.04K |
| EBITDA | -14.02M | -28.12M | -25.72M | -18.35M | -11.74M | -13.95M | -12.48M | -12.53M | -8.91M | -6.30M | -3.31M | -5.86M | -5.35M | -9.28M | -5.73M | -1.62M | -1.62M | -1.34M |
| EBITDA Ratio | -6,231.56% | 0.00% | -1,918.09% | -1,305.74% | -716.54% | -691.18% | -2,811.71% | -3,181.22% | -939.87% | -340.52% | -1,611.71% | -624.63% | -994.23% | -1,312.61% | 0.00% | -139.57% | -164.16% | -149.86% |
| Operating Income | -16.63M | -29.31M | -49.69M | -31.11M | -14.00M | -15.79M | -14.23M | -14.27M | -9.89M | -6.67M | -3.84M | -6.67M | -9.33M | -9.65M | -4.59M | -1.93M | -1.87M | -1.67M |
| Operating Income Ratio | -7,392.89% | 0.00% | -2,085.19% | -1,312.15% | -854.88% | -782.36% | -3,204.28% | -3,622.84% | -1,043.57% | -360.13% | -1,873.17% | -662.07% | -730.19% | -1,856.25% | 0.00% | -163.71% | -189.00% | -185.79% |
| Total Other Income/Expenses | 1.19M | 0.00 | 184.00K | 7.90M | -2.44M | -1.81M | -1.88M | -1.87M | -764.00K | 41.00K | 174.00K | 469.00K | 3.65M | -2.49M | -1.49M | 20.42K | 0.00 | 0.00 |
| Income Before Tax | -15.44M | -29.31M | -50.30M | -23.21M | -16.44M | -17.60M | -16.11M | -16.14M | -10.66M | -6.63M | -3.67M | -6.20M | -5.62M | -12.10M | -6.08M | -1.91M | -1.87M | -1.67M |
| Income Before Tax Ratio | -6,863.56% | 0.00% | -2,110.95% | -979.04% | -1,003.91% | -872.00% | -3,627.93% | -4,096.19% | -1,124.16% | -357.91% | -1,788.29% | -615.49% | -440.34% | -2,327.44% | 0.00% | -161.97% | -189.00% | -185.79% |
| Income Tax Expense | 0.00 | -1.64M | 701.00K | 46.00K | 2.47M | -4.00K | 34.00K | 347.00K | -65.00K | -9.00K | 45.00K | 120.00K | -3.65M | 2.49M | 2.40K | 1.53K | 3.71K | 851.00 |
| Net Income | -24.91M | -29.31M | -51.01M | -23.26M | -18.92M | -17.59M | -16.11M | -14.53M | -9.76M | -6.63M | -3.67M | -6.20M | -5.68M | -12.14M | -6.08M | -1.91M | -1.87M | -1.67M |
| Net Income Ratio | -11,069.78% | 0.00% | -2,140.37% | -980.98% | -1,154.76% | -871.80% | -3,627.25% | -3,688.32% | -1,029.96% | -357.91% | -1,788.29% | -615.49% | -444.35% | -2,334.73% | 0.00% | -162.10% | -189.38% | -185.88% |
| EPS | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| EPS Diluted | -6.50 | -47.87 | -116.97 | -59.45 | -80.53 | -70.50 | -37.87 | -40.77 | -30.15 | -23.17 | -14.56 | -31.38 | -35.92 | -98.02 | -55.65 | -23.53 | -19.92 | -17.76 |
| Weighted Avg Shares Out | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
| Weighted Avg Shares Out (Dil) | 3.83M | 612.25K | 436.05K | 391.25K | 234.90K | 249.54K | 425.24K | 356.44K | 323.89K | 285.98K | 251.87K | 197.52K | 158.02K | 123.88K | 109.21K | 81.06K | 93.83K | 93.83K |
Hot Penny Stocks to Buy in Mid-June 2022? 3 to Watch
What to Know About Buying Penny Stocks on May 23rd
iBio, Inc. (IBIO) CEO Tom Isett on Q3 2022 Results - Earnings Call Transcript
How to Trade Penny Stocks in April 2022 and 3 to Watch
Top Biotech Penny Stocks to Buy Now? 3 to Watch in March
iBio, Inc. (IBIO) CEO Tom Isett on Q2 2022 Results - Earnings Call Transcript
Hot Biotech Penny Stocks to Buy Today? 3 For Your December Watchlist
iBio (IBIO) Stock: Why The Price Surged
IBIO Stock Surges as the Biotech Company Looks to Leverage Omicron Fears
In Light Of Omicron Variant, iBio Issues Update For IBIO-202 COVID-19 Program
Source: https://incomestatements.info
Category: Stock Reports